Consuming refined carbohydrates is linked to a heightened risk of developing type 2 diabetes, not to mention heart disease. But what if a supplement could decrease the breakdown of carbohydrates into simple sugars? That might reduce a person’s risk of developing type 2 diabetes. Our latest study, published in PLOS ONE, shows that an extract made from mulberry leaves might do just that.
Previous research shows that herbal medicines could be effective in regulating blood glucose levels. Indeed, the history of the commonly used diabetic drug metformin can be traced back to the use of a herbal medicine, Galega officinalis (goat’s rue or French lilac) in medieval Europe. G. officinalis was found to be rich in guanidine, a substance with blood glucose-lowering activity that formed the chemical basis of metformin (biguanide). This insulin sensitising drug was introduced in 1957.
Mulberry leaves have been used in traditional Chinese medicine for several millennia and its use was first recorded in around 500AD. In the Grand Materia Medica, it states that “if the juice (of the herb) is decocted and used as a tea substitute it can stop wasting and thirsting disorder”. Wasting (weight loss) and excessive thirst along with increased urination and tiredness are symptoms associated with diabetes. We aimed to investigate the effects of mulberry extract on blood glucose and insulin responses in healthy volunteers with a randomised, double-blind, placebo-controlled clinical trial – the gold standard for a clinical trial.
Promising results
We took blood samples from 37 healthy volunteers after they had consumed a carbohydrate rich drink (containing maltodextrin, a dietary starch with a high glycaemic index that is commonly added to many foods and beverages). Each participant took either a placebo or one of three doses of the extract along with the drink on four separate days. We measured each person’s glucose and insulin levels over the following two hours.
Our analysis showed that the standard strength mulberry extract (250mg) reduced the total glucose and insulin rises by 22% and 24% respectively compared to a placebo. These results were both statistically significant (unlikely to be due to chance) and clinically significant, and thus could have meaningful health benefits. The extract effectively reduced the total amount of sugar being absorbed into the bloodstream by over 20%.
The extract didn’t cause any side effects in the volunteers, such as nausea and flatulence – side effects which are common with many diabetic medications. An active component in the extract, 1-deoxynojirimycin (DNJ), blocks the breakdown of carbohydrates into simple sugars, preventing the absorption of sugar, lowering blood-glucose rises. Although mulberry leaves can be used to make tea, the particular extract we used had undergone strict quality control processes in order to guarantee consistency of its DNJ content.
In order to draw definitive conclusions about the long-term health benefits of mulberry leaf extract, longer, more pragmatic trials reflecting real-life dietary habits are needed to show if this herbal supplement could prevent the development of type 2 diabetes. The initial results are certainly promising.
Mark Lown received funding from a Technology Strategy Board grant
George Lewith receives funding the Technology strategy board for this project.


FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 



